Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson’s disease: A pilot, randomized, assessor-blinded clinical trial

Chul Jin¹, Ki-Ho Cho², Seungwon Kwon³, Han-Gyul Lee², Tae-Hun Kim³, Woo-Sang Jung², Sang-Kwan Moon², Seung-Yeon Cho¹, Byoung-Kab Kang⁴, Jung-Mi Park⁵, and Chang-Nam Ko⁴

¹Department of Korean Medicine Cardiology and Neurology, Graduate School, Kyung Hee University, Seoul, South Korea, ²Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Kyung Hee University Medical Center, Seoul, South Korea, ³Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, South Korea, ⁴Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Kyung Hee University Hospital at Gangdong, Seoul, South Korea, ⁵KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea, ⁶Acupuncture and Meridian Science Research Center, College of Korean Medicine, Kyung Hee University, Seoul, South Korea

Objectives: Parkinson's disease (PD) is a neurodegenerative disease in which patients are suffering various symptoms. Previous experimental studies suggested that herbal medicine Ukgansan (UGS) could be beneficial for PD. The aim of this pilot clinical trial was to evaluate the efficacy of UGS for improving clinical symptoms in patients with PD.

Methods: Sixty patients with idiopathic PD were randomly assigned to receive either UGS plus acupuncture or acupuncture alone for 6 weeks. During the trial, all anti-parkinsonian medications were maintained. Subjects were evaluated for various clinical assessments of PD, including the Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS) and the 39-item Parkinson’s Disease Questionnaire (PDQ-39), until 12 weeks.

Results: In MDS-UPDRS between the groups, no significant time x group interaction was found. In the subgroup analysis of participants with anxiety, a significant time x group interaction was found in the PDQ-39 domain of mobility ($P = 0.007$), activities of daily living ($P = 0.042$), and the PDQ-39 summary index ($P = 0.048$). In addition, post-hoc analysis in participants with anxiety showed a significant decrease in the domains of mobility ($P = 0.001$) and activities of daily living ($P = 0.013$) at week 7. There were no adverse events associated with UGS.

Conclusion: The additional administration of UGS has the potential to significantly improve the quality of life of PD patients with anxiety. In order to create more definitive evidence, clinical trials with more rigorous methodologies should be conducted in future.
Introduction

Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder, with a prevalence of 2–3% in the elderly population (1). In 2015, 6.2 million people worldwide were diagnosed with PD, and the number is projected to be over 12 million by 2040 (2).

Parkinson’s disease (PD) is characterized by a lack of dopamine within basal ganglia due to cell loss of dopaminergic neurons in the substantia nigra, resulting in motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. Therefore, the gold-standard treatment of PD is to alleviate parkinsonian symptoms with drugs that increase dopamine concentrations (levodopa) or directly stimulate dopamine receptors (dopamine agonists) (3). However, long-term use of anti-PD medications reduces their effectiveness and causes side effects such as neuropsychiatric symptoms and motor complications. In addition, PD patients are suffered from not only motor symptoms, but also numerous non-motor symptoms, such as depression, fatigue, sleep disorder, cognitive impairment, autonomic dysfunction, and pain which might start in the prodromal phase of PD (1, 3). Thus, managing these various symptoms of PD requires a variety of therapeutic options in addition to conventional therapy.

Complementary alternative medicine (CAM) treatments for PD include meditation, qigong, yoga, dance, massage, acupuncture, and herbal medicine (4). Among them, acupuncture has been used as an effective therapeutic option in patients with PD in eastern Asia (5). Previous clinical trials have shown that acupuncture has the clinical efficacy to improve motor symptoms and some non-motor symptoms in patients with PD (6). Furthermore, acupuncture has also been found to protect dopaminergic neurons from degeneration by altering the neurotransmitter balance in the basal ganglia circuit and reducing oxidative stress, inflammation, and apoptosis (7).

As another option, that herbal medicine as an adjunct therapy can help improve motor and non-motor symptoms of PD (8, 9). Ukgansan (UGS, Yokukansan in Japanese, Yigansan in Chinese) is an herbal medicine formula that may benefit the treatment of PD and that has been shown to protect dopaminergic neurons and to supplement dopamine concentration (10, 11). However, the therapeutic role of UGS in patients with PD is debatable. UGS has improved neuropsychiatric symptoms but not motor function in clinical trials for PD (12, 13). Therefore, an exploratory pilot clinical trial to determine whether UGS helps improve clinical symptoms of PD is needed. The present pilot study explored the efficacy and safety of UGS for improving clinical symptoms in patients with PD.

Materials and methods

Study design

This study was a single-centered, randomized controlled, assessor-blinded, active-controlled, parallel-group, pilot clinical trial conducted at the Kyung Hee University Korean Medicine Hospital (Seoul, Republic of Korea) between December 2018 and November 2020. The protocol was registered with the Clinical Research Information Service (CRIS, KCT0003444) and approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital (KOMCIRB-170717-HR-02).

Participants were recruited through advertisements, which are poster ads on bulletin boards of the hospital and the subway. This pilot trial had three consecutive periods: screening period (week 0), intervention period (weeks 1–6), and observation period (weeks 7–12). All prospective participants were questioned by phone by the clinical research coordinator (CRC) to check their medications and PD duration before being scheduled for a screening visit (Visit 0). At the screening visit, patients who voluntarily agreed to participate in the clinical trial were evaluated on the inclusion and exclusion criteria, including blood sampling and electrocardiogram (ECG).

At week 1, baseline measurements were taken on eligible participants. After that, they were randomly assigned to one of two groups, the control group (only acupuncture + medications related to Parkinson’s disease) or the treatment group (UGS + acupuncture + medications related to Parkinson’s disease) in a 1:1 ratio. From that day on, participants in both groups maintained medications related to Parkinson’s disease and were treated for acupuncture two times a week for 6 weeks. The treatment group was also prescribed UGS for the same period. Measurements for evaluations were taken at week 7 and week 12 (Figure 1).
If the following situation occurred while participating in the study, it was treated as a withdrawal:

1. Violation of the inclusion or exclusion criteria after enrollment,
2. Withdrawal of consent by the participants (or their legal representative),
3. Request for discontinuance of the trial or refusal to receive intervention by the participants (or their legal representative),
4. Loss to follow-up,
5. Serious adverse events (e.g., hospitalization or life-threatening events, etc.) or exacerbation of illnesses that made it difficult to continue participation,
6. Less than 80% compliance of clinical trial medication (UGS) administration and/or acupuncture treatment,
7. Violation of the clinical trial protocol,
8. Other inappropriate conditions for study participation as judged by the investigator.

Participants

Participants who met the following criteria were selected as subjects of the present study.

Inclusion criteria
1. Males or females aged 45–80 years,
2. Patients with idiopathic Parkinson’s disease taking levodopa for more than 5 years (without anti-cholinergic drugs),
3. Hoehn and Yahr stages 2–3,
4. Patients without cognitive impairment who have voluntarily agreed to participate.

Exclusion criteria
1. Patients diagnosed with secondary parkinsonism or atypical parkinsonian syndrome,
2. Diseases that might affect the administration or absorption of drugs (e.g., dysphagia, clinically severe digestive disorders, galactose intolerance, Lapp lactase deficiency, or glucose–galactose malabsorption),
3. Previous history of severe heart disease (myocardial infarction, heart failure, etc.),
4. Patients receiving neurosurgical treatment (e.g., deep brain stimulation),
5. Patients with glaucoma,
6. Patients who were diagnosed or treated for cancer within 5 years,
7. Chronic alcohol consumption or drug abuse,
8. Patients with a history of allergy to the test drug (UGS),
9. Patients with liver disease or kidney disease (aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), or creatinine >x3 of normal upper limit),
10. Women who were planning pregnancy, pregnant, or breastfeeding,
11. Participation in other clinical trials within 30 days,
12. Patients who were judged by the investigator to be unsuitable for participation in the trial due to psychiatric symptoms, medical illness, laboratory findings, etc.
Interventions

All participants maintained medications related to Parkinson’s disease (levodopa, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, amantadine, etc.) except for anti-cholinergic drugs, which had been taken as before.

Control group

The acupuncture therapy was performed two times a week for 6 weeks on participants in the control arm. Acupuncture was conducted by a Korean medical doctor with more than 7 years of clinical expertise in internal medicine. The STRICTA checklist included instructions on how to practice acupuncture (Table 1) (14).

Treatment group

Participants in the treatment group received the same acupuncture procedure as the control group and additional administration of UGS. UGS, an herbal extract granule, was produced and packaged by KYUNGJIN PHARM.CO.LTD. (Icheon, South Korea), one of the Korean Good Manufacturing Practice (KGMP)-certified companies, for this clinical trial under the approval of the Ministry of Food and Drug Safety’s Investigational New Drug (IND). The composition of UGS is described in Table 2. At visits 1, 5, and 9, participants were provided with individually packed UGS (14 days + an extra 2 days). UGS was provided by an independent pharmacist in a separate place, and participants were required to take that medicine with water at 10 a.m. and 5 p.m. for 6 weeks.

Outcomes

Primary outcome

The primary outcome of this study was a change in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) total score after treatment (week 7 minus baseline), between the two groups (15).

Secondary outcomes

The secondary outcomes included MDS-UPDRS part I–IV, trends of changes in MDS-UPDRS, the modified Hoehn and Yahr staging scale (H–Y scale), Schwab and England Activities of Daily Living (SE-ADL) Scale, Berg balance test (BBT), Timed-up-and-go (TUG) test, 39-item Parkinson’s Disease Questionnaire (PDQ-39) including the PDQ-39 summary index (PDQ-39 SI), and five-level version of European Quality of Life Scale Five-Dimensional Questionnaire (EQ-5D-5L) score (16, 17). All these measured outcomes were compared between the two groups with the changes in difference from baseline.

TABLE 1 Revised STRICTA* checklist.

| 1. Acupuncture rationale | 1a) Manual acupuncture
| 1b) Based on a systematic review and expert consensus
| 1c) Unacceptable
| 2. Details of needling | 2a) 23 points
| 2b) GV20, bilateral EX-HN5, GB20, LI4, TE5, LI10, LI11, GB34, ST36, GB39, LR3, GB41†
| 2c) 5-10mm
| 2d) De-qi
| 2e) Manual stimulation
| 2f) 20 minutes
| 2g) Sterilized stainless steel needle (diameter 0.25mm, length 40mm, Dongbang Medical co., Seongnam, South Korea)
| 3. Treatment regimen | 3a) 12 sessions
| 3b) two times a week for 6 weeks
| 4. Other components of treatment | 4a) The purpose of this study was to verify the additional effects of UGS when used in conjunction with acupuncture. As a result, during the intervention time, the treatment group received UGS two times a day, and the anti-Parkinson’s medicine remained the same.
| 5. Practitioner background | 5) All acupuncture procedures were performed by one Korean Medicine Doctor with more than 7 years of clinical experience.
| 6. Control interventions | 6a) Based on the systematic review and expert consensus
| 6b) Same as acupuncture procedure of the treatment group

† Standards for Reporting Interventions in Clinical Trials of Acupuncture.
1 The terminology was followed as the WHO Standard Acupuncture Point Locations in the Western Pacific Region.

Safety assessment

Vital signs and adverse events were measured at each visit. ECG and blood sampling were performed at the screening visit and week 7. Blood sampling includes the white blood cell count (WBC), red blood cell count (RBC), hemoglobin (Hb), hematocrit (Hct), platelet count, BUN, creatinine, AST, ALT, glucose, and electrolytes (Na, K, Cl).

Sample size calculation

This clinical trial was to verify the additional improvement in MDS-UPDRS total score following the administration of
TABLE 2 Composition of Ukgansan*.

| Scientific name | Herbal name               | Amount (g) |
|-----------------|---------------------------|------------|
| Atractylodes lancea De Candolle | Atractylodis Rhizoma | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |
| Magnolia officinalis Rehder et Wilson | Magnoliae Cortex | 4          |
| Poria cocos Wolf          | Poria Sclerotium        | 4          |
| Gymnema sylvestre        | Gymnemae Sylvestre        | 3          |

* The Ukgansan used in this study was modified by adding Magnoliae Cortex and Ponciri Fructus Immaturus to original Ukgansan.

herbal medicine UGS. The effect size was calculated from the previous study which was conducted to validate the effect of herbal medicine UGS. The effect size was calculated from the original Ukgansan.

The pooled standard deviation of the UPDRS total score at post-treatment in a previous similar study was 16.64. And a minimal clinical important difference (CID) on the UPDRS total score was 4.3 points (19). Assuming the mean difference of 4.3 and the standard deviation of 16.64, the calculated effect size was 0.258. We calculated the sample size using stepped rules of thumb for pilot sample size, using a two-tailed type I error rate of 5% and a power of 90%. As a result, each group required 25 participants (20). Sixty participants, 30 in each group, were recruited, anticipating a 15% drop-out rate similar to the previous study (21).

Randomization, allocation concealment, and blinding

An independent statistician generated random numbers by block randomization using STATA (version 4.2; StataCorp LLC, Texas, USA). The random assignment code was placed in opaque sealed envelopes and delivered to the Kyung Hee University Korean Medicine Hospital. The investigator opened the consecutive numbered sealed envelope in front of the participant whose screening criteria were satisfied and assigned them to the intervention or control group. All opened envelopes were kept safely and separately.

The design of this study does not include placebo as a control, therefore, the participants and practitioners cannot be blinded. However, the separate assessor who was responsible for evaluating efficacy and safety was blinded to prevent access to the allocation results.

Statistical analysis

At baseline assessments, continuous data were expressed as means and standard deviations and analyzed with either the two-sample t-test or the Wilcoxon rank-sum test. Categorical variables were represented as frequencies or percentages, and the Chi-square test or Fisher's exact test was used to assess them.

The effectiveness analysis was preferentially performed using the full analysis set (FAS), including participants who had been treated more than once after participating in the clinical trial. If necessary, the per-protocol set (PPS) was performed, including participants who had completed the clinical trial plan. In the FAS analysis, missing data were handled with the last-observation-carried-forward (LOCF) analysis imputation method.

The MDS-UPDRS score changes in primary and secondary outcomes, between baseline (before the randomization) and week 7 (1 week after 6 weeks of treatment), were compared between the two groups using either the two-sample t-test or the Wilcoxon rank-sum test. A repeated measures analysis of variance (ANOVA) was used to examine the trend of changes in the MDS-UPDRS score between groups depending on the time. The modified H–Y scale evaluated at two endpoints was classified as an improvement, no change, or aggravation, compared with baseline. And the improvement ratio between groups was conducted using the Chi-square test or Fisher's exact test. The other secondary outcomes, comparing the change scores between groups at weeks 7 and 12, were analyzed using the same methods as the primary outcome. The significance of the statistical values between groups at each time point was evaluated using an independent t-test as a post-hoc analysis.

The safety of treatment was assessed using the safety analysis set (SAS) method, which included all subjects who had been treated at least once. And the Chi-square test or Fisher's exact test was used whether there were any differences in the incidence ratio between the groups.

This pilot clinical trial was conducted with a two-sided test to determine significance at the 5% level (α = 0.05). In the post-hoc test, the Bonferroni correction was applied to test the significance (statistically significant when p < 0.016). All statistical analyses were performed using the IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, NY, USA).

Results

Baseline characteristics

A total of 64 patients were screened for eligibility. Of these 64, three did not meet the inclusion criteria, one
Study flow diagram. UGS, Ukgansan; AT, acupuncture; COVID-19, coronavirus disease 2019.

At the repeated measures analysis of variance used to determine the trend of change in MDS-UPDRS between the groups, no significant time x group interaction was found. In the total MDS-UPDRS score and part III total score, however, only the time effect was significant, indicating that the two scores tended to decrease until the 12-week observation period (Table 4).

In both groups, the MDS-UPDRS total score and MDS-UPDRS part I–IV score measured at week 7 decreased from baseline. However, the difference in total MDS-UPDRS score from baseline at week 7, which was a primary outcome, did not show any significance between the two groups (95% CI: –0.82 to
TABLE 3  Demographic and baseline characteristics.

| Characteristics          | Treatment group (n = 30) | Control group (n = 30) | P value   |
|--------------------------|--------------------------|------------------------|-----------|
| Age, mean (SD), years    | 66.87 (8.04)             | 64.27 (7.18)           | 0.192     |
| Male, n (%)              | 15 (50.00)               | 19 (63.33)             | 0.297     |
| BMI, mean (SD), kg/m²    | 22.51 (2.56)             | 23.92 (2.96)           | 0.053     |
| Employment status        |                          |                        |           |
| Employed, n (%)          | 3 (10.00)                | 1 (3.33)               |           |
| Unemployed, n (%)        | 27 (90.00)               | 29 (96.67)             | 0.612     |
| Education                |                          |                        |           |
| Primary school, n (%)    | 17 (56.67)               | 8 (26.67)              |           |
| Middle school, n (%)     | 7 (23.33)                | 13 (43.33)             |           |
| High school, n (%)       | 3 (10.00)                | 7 (23.33)              |           |
| College or higher, n (%) | 3 (10.00)                | 2 (6.67)               | 0.074     |
| PD history, mean (SD), years | 9.27 (3.77)            | 9.10 (3.36)            | 0.857     |
| Levodopa dosage, mean (SD), mg/day | 626.67 | 691.67 | 0.336  |
| MDS-UPDRS total score, mean (SD) | 57.47 (20.35) | 58.63 (26.67) | 0.850  |
| MDS-UPDRS part I, mean (SD) | 12.40 (6.08) | 13.53 (7.82) | 0.533  |
| MDS-UPDRS part II, mean (SD) | 14.37 (7.54) | 15.10 (8.47) | 0.724  |
| MDS-UPDRS part III, mean (SD) | 27.77 (13.71) | 26.07 (14.12) | 0.638  |
| MDS-UPDRS part IV, mean (SD) | 2.93 (3.34) | 3.93 (3.84) | 0.286  |
| Modified Hoehn–Yahr stage |                          |                        |           |
| Stage 2, n (%)           | 25 (83.33)               | 23 (76.67)             |           |
| Stage 2.5, n (%)         | 1 (3.33)                 | 2 (6.67)               |           |
| Stage 3, n (%)           | 4 (13.33)                | 5 (16.67)              | 0.794     |
| BBT, mean (SD)           | 53.00 (3.24)             | 51.73 (4.95)           | 0.245     |
| TUG, mean (SD), sec      | 8.56 (2.80)              | 9.49 (6.58)            | 0.484     |
| SE-ADL, mean (SD), %     | 82.00 (10.64)            | 83.00 (12.08)          | 0.735     |
| Domains of PDQ-39, mean (SD), % |            |                        |           |
| Mobility                 | 27.58 (19.78)            | 29.17 (23.22)          | 0.777     |
| Activities of Daily Living | 29.31 (19.50)          | 25.56 (24.34)          | 0.513     |
| Emotional well-being     | 29.86 (23.85)            | 31.67 (24.29)          | 0.772     |
| stigma                   | 24.17 (16.47)            | 28.96 (23.81)          | 0.369     |
| Social support           | 27.22 (22.52)            | 20.28 (19.41)          | 0.206     |
| Cognition                | 29.79 (21.88)            | 25.63 (21.17)          | 0.457     |
| Communication            | 23.61 (19.34)            | 23.06 (24.04)          | 0.922     |
| Bodily discomfort         | 28.89 (23.03)            | 31.94 (21.23)          | 0.595     |
| PDQ-39 SI, mean (SD), %  | 27.55 (16.11)            | 27.03 (19.32)          | 0.910     |
| EQ-5D Index score, mean (SD) | 0.72 (0.11)               | 0.70 (0.15)            | 0.440     |
| EQ-5D VAS, mean (SD), mm | 71.70 (13.75)            | 73.23 (16.38)          | 0.696     |

BMI, body mass index; PD, Parkinson’s disease; MDS-UPDRS, the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; BBT, Berg balance test; TUG, Timed Up and Go test; SE-ADL, Schwab and England Activities of Daily Living Scale; PDQ-39, 39-item Parkinson’s Disease Questionnaire; PDQ-39 SI, PDQ-39 summary index; EQ-5D, five-level version of European Quality of Life Scale Five-Dimensional Questionnaire; VAS, Visual analog scale.

P value was calculated using independent t-test or Wilcoxon rank-sum test.

6.22; P = 0.801). Similarly, there were no significant differences in MDS-UPDRS part I-IV scores between the two groups after treatment (Table 5).

H–Y scale

At the two outcome points, weeks 7 and 12, no significant difference in H–Y scale changes was observed between the two groups (P = 1.00 and P = 0.240, respectively) (Table 6).

Other outcomes (BBT, TUG, SE-ADL, PDQ-39, and EQ-5D-5L)

There were no significant interaction effects evaluated by repeated measures ANOVA in all measured outcomes. Between the two groups, there were no significant differences in the BBT, TUG, SE-ADL, PDQ-39 SI, PDQ-39 domains, EQ-5D index score, and EQ-5D VAS (Table 7).

PDQ-39 domains and summary index in anxiety group

All subjects who answered no to item 21 (anxious) on the PDQ-39 were eliminated, and only those with anxiety were subjected to subgroup analysis. In a subgroup of anxiety, post-hoc analysis was performed on the PDQ-39. In this subgroup analysis, Cronbach’s alpha value for PDQ-39 was 0.926, which showed high reliability.

In a repeated measures ANOVA to investigate changes between the two anxiety groups over time, the PDQ-39 SI score, mobility domain, and activities of daily living domain showed a significant time x group interaction effect (P = 0.048, P = 0.007, and P = 0.042, respectively, Table 8). And comparing the differences from baseline between the two groups, the treatment group with anxiety showed a significant improvement in the domains of mobility and activities of daily living compared with the control group with anxiety at week 7 (P = 0.001, P = 0.013, respectively, Table 8).

Safety

For the safety analysis, a total of 60 subjects were included. There were no serious adverse events in either group, and the trial was not terminated due to any adverse events. A subject in the treatment group reported mild dizziness (n = 1, 3.33 %). After acupuncture treatment, that participant experienced mild dizziness, which went away after a brief rest. At week 7, a subject in the control group (n = 1, 3.33 %) reported an increase in
The trend of changes during 12 weeks in the MDS-UPDRS score between groups depending on the time using repeated measures analysis of variance.

| Variable                  | Time       | Treatment group \((n = 30)\) | Control group \((n = 30)\) | Source     | F value | \(P\) value |
|---------------------------|------------|--------------------------------|-----------------------------|------------|---------|-------------|
| Total MDS-UPDRS score     | Baseline   | 57.47 ± 20.35                  | 58.63 ± 26.67               | Group      | 0.008   | 0.930       |
|                           | Week 7     | 53.03 ± 18.55                  | 53.30 ± 24.01               | Time       | 8.406   | 0.001       |
|                           | Week 12    | 52.13 ± 21.89                  | 49.23 ± 25.20               | Time x group | 0.683   | 0.489       |
| MDS-UPDRS Part I score    | Baseline   | 12.49 ± 6.08                   | 13.53 ± 7.82                | Group      | 0.169   | 0.682       |
|                           | Week 7     | 11.90 ± 5.64                   | 12.30 ± 6.57                | Time       | 2.076   | 0.138       |
|                           | Week 12    | 11.63 ± 4.82                   | 11.93 ± 6.75                | Time x group | 0.286   | 0.717       |
| MDS-UPDRS Part II score   | Baseline   | 14.37 ± 7.54                   | 15.10 ± 8.47                | Group      | 0.217   | 0.643       |
|                           | Week 7     | 13.60 ± 6.20                   | 15.00 ± 9.29                | Time       | 0.225   | 0.799       |
|                           | Week 12    | 14.07 ± 8.06                   | 14.57 ± 8.12                | Time x group | 0.204   | 0.816       |
| MDS-UPDRS Part III score  | Baseline   | 27.77 ± 13.71                  | 26.07 ± 14.12               | Group      | 0.777   | 0.382       |
|                           | Week 7     | 24.80 ± 15.05                  | 22.13 ± 12.58               | Time       | 10.889  | <0.001      |
|                           | Week 12    | 23.97 ± 14.17                  | 19.50 ± 13.62               | Time x group | 0.771   | 0.447       |
| MDS-UPDRS Part IV score   | Baseline   | 2.93 ± 3.34                    | 3.93 ± 3.84                 | Group      | 1.274   | 0.264       |
|                           | Week 7     | 2.73 ± 3.56                    | 3.87 ± 4.13                 | Time       | 2.025   | 0.137       |
|                           | Week 12    | 2.47 ± 2.78                    | 3.23 ± 3.71                 | Time x group | 0.187   | 0.830       |

MDS-UPDRS, the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Values are presented as mean ± standard deviation.

The difference in MDS-UPDRS scores between groups from baseline to week 7.

| Treatment group \((n = 30)\) | Control group \((n = 30)\) | Mean difference | 95% confidence interval (CI) | \(P\) value | Effect size |
|-----------------------------|----------------------------|-----------------|----------------------------|-------------|-------------|
| Total MDS-UPDRS score       | −4.43 ± 14.04              | −5.33 ± 13.50   | −0.90                      | −8.02 to 6.22 | 0.801       | 0.065       |
| Part I score (non–motor symptom) | −0.50 ± 4.97              | −1.23 ± 5.07    | −                        | −           | 0.868       | 0.145       |
| Part II score (motor symptom) | −0.77 ± 5.79              | −0.10 ± 5.17    | −                        | −           | 0.747       | 0.122       |
| Part III score (motor examination) | −2.97 ± 8.53              | −3.93 ± 8.75    | −0.97                     | −5.43 to 3.50 | 0.666       | 0.111       |
| Part IV score (motor complications) | −0.20 ± 2.62              | −0.07 ± 2.53    | −                        | −           | 0.760       | 0.050       |

MDS-UPDRS, the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Values are presented as mean ± standard deviation. \(P\) value was calculated using independent t-test or Wilcoxon rank-sum test. Effect size was calculated using Cohen's D.

Comparison of H–Y scale improvement rates between groups.

| Change of H–Y scale | Treatment group \((n = 30)\) | Control group \((n = 30)\) | \(P\) value |
|---------------------|-------------------------------|-----------------------------|-------------|
| Week 7–baseline     | Improvement 10 (33.3)         | 10 (33.3)                   | 1.00        |
|                     | No change 19 (63.3)           | 20 (66.7)                   |             |
|                     | Aggravation 1 (3.3)           | 0 (0)                       |             |
| Week 12–baseline    | Improvement 12 (40.0)         | 18 (60.0)                   | 0.240       |
|                     | No change 17 (56.7)           | 11 (36.7)                   |             |
|                     | Aggravation 1 (3.3)           | 1 (3.3)                     |             |

H–Y scale, Modified Hoehn–Yahr stage scale. \(P\) value was calculated by Fisher's exact test.
TABLE 7  Comparison of other outcomes between two groups.

| Week | Treatment group | Control group | Source |      |        |
|------|----------------|---------------|--------|------|--------|
|      | (n = 30)       | (n = 30)      |        |      |        |
| BBT  | 0              | 53.00 ± 3.24  | 52.07 ± 4.59 | Group | 0.665  |
|      | 7              | 53.27 ± 2.97  | 53.33 ± 4.33 | Time  | 0.007  |
|      | 12             | 53.63 ± 3.31  | 53.27 ± 4.54 | T × G | 0.236  |
|      | TUG            | 8.56 ± 2.80   | 9.49 ± 6.58  | Group | 0.521  |
|      | 7              | 7.71 ± 2.56   | 8.55 ± 6.56  | Time  | <0.001 |
|      | 12             | 7.90 ± 2.89   | 8.63 ± 6.66  | T × G | 0.844  |
|      | SE-ADL         | 82.00 ± 10.64 | 83.00 ± 12.08| Group | 0.680  |
|      | 7              | 84.00 ± 13.03 | 82.00 ± 12.15| Time  | 0.232  |
|      | 12             | 85.67 ± 8.58  | 83.33 ± 13.22| T × G | 0.320  |
|      | PDQ-39 SI      | 27.55 ± 16.11 | 27.03 ± 19.32| Group | 0.884  |
|      | 7              | 25.24 ± 15.78 | 26.62 ± 18.22| Time  | 0.620  |
|      | 12             | 26.04 ± 16.95 | 27.07 ± 19.47| T × G | 0.768  |
|      | Mobility       | 27.58 ± 19.78 | 29.17 ± 23.22| Group | 0.287  |
|      | 7              | 22.42 ± 19.60 | 32.08 ± 23.20| Time  | 0.676  |
|      | 12             | 24.25 ± 18.17 | 29.17 ± 22.93| T × G | 0.111  |
|      | Activities of  | 29.31 ± 19.50 | 25.56 ± 24.34| Group | 0.687  |
| DailyLiving | 7              | 26.81 ± 20.17 | 27.36 ± 23.13| Time  | 0.676  |
|      | 12             | 30.42 ± 22.51 | 27.22 ± 24.07| T × G | 0.530  |
|      | Emotional      | 29.86 ± 23.85 | 31.67 ± 24.29| Group | 0.592  |
|      | 7              | 25.14 ± 20.19 | 28.47 ± 24.12| Time  | 0.106  |
|      | 12             | 26.11 ± 21.24 | 30.00 ± 25.22| T × G | 0.850  |
|      | Stigma         | 24.17 ± 16.47 | 28.96 ± 23.81| Group | 0.572  |
|      | 7              | 25.83 ± 17.43 | 26.67 ± 23.21| Time  | 0.414  |
|      | 12             | 22.92 ± 18.95 | 25.83 ± 24.44| T × G | 0.539  |
|      | Social support | 27.22 ± 22.52 | 20.28 ± 19.41| Group | 0.404  |
|      | 7              | 24.72 ± 21.27 | 19.44 ± 20.57| Time  | 0.632  |
|      | 12             | 24.17 ± 24.21 | 23.61 ± 22.11| T × G | 0.289  |
|      | Cognition      | 29.79 ± 21.88 | 25.63 ± 21.17| Group | 0.616  |
|      | 7              | 27.29 ± 21.49 | 25.63 ± 18.30| Time  | 0.748  |
|      | 12             | 28.54 ± 22.72 | 27.08 ± 20.52| T × G | 0.748  |
|      | Communication  | 23.61 ± 19.34 | 23.06 ± 24.04| Group | 0.889  |
|      | 7              | 23.33 ± 19.99 | 23.06 ± 23.02| Time  | 0.857  |
|      | 12             | 24.72 ± 19.14 | 23.33 ± 25.37| T × G | 0.933  |
|      | Bodily discomfort| 28.89 ± 23.05 | 31.94 ± 21.23| Group | 0.529  |
|      | 7              | 26.39 ± 23.27 | 30.28 ± 17.84| Time  | 0.447  |
|      | 12             | 27.22 ± 24.26 | 30.28 ± 21.27| T × G | 0.942  |
|      | EQ-5D Index score| 0.72 ± 0.11  | 0.70 ± 0.15  | Group | 0.462  |
|      | 7              | 0.73 ± 0.13   | 0.73 ± 0.12  | Time  | 0.101  |
|      | 12             | 0.73 ± 0.13   | 0.69 ± 0.16  | T × G | 0.417  |
|      | EQ-5D VAS      | 71.70 ± 13.75 | 73.23 ± 16.38| Group | 0.840  |
|      | 7              | 68.50 ± 15.60 | 70.30 ± 19.10| Time  | 0.094  |
|      | 12             | 73.70 ± 16.25 | 72.67 ± 18.88| T × G | 0.694  |

BTT, Berg balance test; TUG, Timed Up and Go test; SE-ADL, Schwab and England Activities of Daily Living Scale; PDQ-39, 39-item Parkinson's Disease Questionnaire; PDQ-39 SI, PDQ-39 summary index; EQ-5D, five-level version of European Quality of Life Scale Five-Dimensional Questionnaire; VAS, Visual analog scale; T, Time; G, Group.

Values are presented as mean ± standard deviation.

*P value was calculated using repeated measures ANOVA.
†P value was calculated comparing differences from baseline (Δ score) between groups by independent t-test or Wilcoxon rank-sum test.
TABLE 8 Comparison PDQ-39 domains and summary index between groups with anxiety.

| Week | Treatment group with anxiety (n = 17) | Control group with anxiety (n = 20) | Source | P value* | P value† |
|------|-----------------------------------|-----------------------------------|--------|----------|----------|
|      | PDQ-39 SI                         |                                   |        |          |          |
| 0    | 31.93 ± 15.80                     | 27.67 ± 17.61                     | Group  | 0.847    | –        |
| 7    | 25.17 ± 14.94                     | 28.89 ± 17.10                     | Time   | 0.312    | 0.056    |
| 12   | 26.37 ± 16.70                     | 29.93 ± 18.50                     | T × G  | 0.048    | 0.020    |
|      | Domains of PDQ-39                 |                                   |        |          |          |
|      | Mobility                          |                                   |        |          |          |
| 0    | 31.32 ± 19.12                     | 29.63 ± 19.96                     | Group  | 0.190    | –        |
| 7    | 19.41 ± 17.49                     | 35.63 ± 21.32                     | Time   | 0.365    | 0.004    |
| 12   | 23.09 ± 14.91                     | 31.13 ± 21.38                     | T × G  | 0.007    | 0.038    |
|      | Activities of Daily Living        |                                   |        |          |          |
| 0    | 35.29 ± 18.81                     | 24.79 ± 21.44                     | Group  | 0.651    | –        |
| 7    | 26.47 ± 19.65                     | 29.58 ± 22.21                     | Time   | 0.695    | 0.013    |
| 12   | 30.64 ± 21.29                     | 29.38 ± 23.70                     | T × G  | 0.042    | 0.024    |
|      | Emotional Wellbeing               |                                   |        |          |          |
| 0    | 37.75 ± 20.96                     | 34.17 ± 19.00                     | Group  | 0.927    | –        |
| 7    | 28.92 ± 20.49                     | 31.25 ± 21.27                     | Time   | 0.084    | 0.434    |
| 12   | 30.15 ± 21.93                     | 33.13 ± 23.12                     | T × G  | 0.410    | 0.365    |
|      | Stigma                            |                                   |        |          |          |
| 0    | 26.10 ± 18.25                     | 30.31 ± 22.88                     | Group  | 0.460    | –        |
| 7    | 25.00 ± 17.54                     | 29.38 ± 22.31                     | Time   | 0.465    | 0.981    |
| 12   | 22.43 ± 17.12                     | 27.81 ± 24.37                     | T × G  | 0.969    | 0.921    |
|      | Social support                    |                                   |        |          |          |
| 0    | 32.84 ± 24.20                     | 19.58 ± 18.19                     | Group  | 0.320    | –        |
| 7    | 28.92 ± 21.67                     | 21.25 ± 20.32                     | Time   | 0.761    | 0.341    |
| 12   | 26.47 ± 26.72                     | 28.33 ± 21.01                     | T × G  | 0.057    | 0.004    |
|      | Cognition                          |                                   |        |          |          |
| 0    | 35.29 ± 22.53                     | 27.50 ± 21.69                     | Group  | 0.961    | –        |
| 7    | 24.63 ± 18.42                     | 27.81 ± 19.29                     | Time   | 0.161    | 0.040    |
| 12   | 27.21 ± 19.51                     | 30.94 ± 21.12                     | T × G  | 0.059    | 0.024    |
|      | Communication                      |                                   |        |          |          |
| 0    | 25.49 ± 17.30                     | 20.00 ± 21.19                     | Group  | 0.491    | –        |
| 7    | 24.02 ± 20.17                     | 20.83 ± 19.21                     | Time   | 0.801    | 0.502    |
| 12   | 25.98 ± 19.07                     | 22.08 ± 23.77                     | T × G  | 0.898    | 0.774    |
|      | Bodily discomfort                  |                                   |        |          |          |
| 0    | 31.37 ± 23.85                     | 35.42 ± 23.71                     | Group  | 0.184    | –        |
| 7    | 24.02 ± 19.07                     | 35.42 ± 23.90                     | Time   | 0.235    | 0.222    |
| 12   | 25.00 ± 21.45                     | 36.67 ± 22.52                     | T × G  | 0.166    | 0.151    |

PDQ-39, 39-item Parkinson’s Disease Questionnaire; PDQ-39 SI, PDQ-39 summary index; T, Time; G, Group.

*P value was calculated using repeated measures ANOVA.
†P value was calculated comparing differences from baseline (Δ score) between groups by Mann–Whitney’s U test.

WBC. WBC elevation was thought to be caused by a common cold, and after re-examination at a follow-up visit, it returned to normal. Aside from that, there were no adverse events with clinical abnormalities, vital signs, blood samples, or ECG.

Discussion

In comparison with the control group, the treatment group did not reveal significant changes in the MDS-UPDRS score at week 7 and other outcomes at weeks 7 and 12. In subgroup analysis of anxiety participants, a significant time × group interaction was found in the PDQ-39 domain of mobility, activities of daily living, and the PDQ-39 summary index. In the post-hoc analysis of PDQ-39 on patients with anxiety who responded to item 21 (anxious) of PDQ-39, significant differences between the two groups were detected in the domains of mobility and activities of daily living at week 7.

In line with these real-world clinical situations of Korea, we planned to apply acupuncture treatment in the same regimen for both the test group and the control group. Acupuncture is the most common treatment for patients with PD who visit a Korean medicine hospital for outpatient, followed by herbal medicine (22). At actual clinical sites of Korean medicine, using herbal medicine alone without acupuncture for PD is unusual unless there are extraordinary cases, such as needle phobia. There are two reasons: The first is that acupuncture is an effective and safe treatment for PD and the second is that it is covered by Korean national health insurance, so the cost burden is minimal. Therefore, acupuncture is performed in almost all patients with PD by
Korean medical doctors, but herbal medicine is administered as necessary.

The pattern identification in traditional East Asian medicine, which is a pattern of symptom manifestation that varies between individuals, is used in clinical herbal medicine to make diagnoses and prescribe medicine. And UGS was traditionally used to treat neurosis, insomnia, night crying, and irritability in children. UGS had been shown in previous studies to improve neuropsychiatric symptoms such as aggression, agitation, and anxiety in patients with PD or Alzheimer's disease (12, 13, 23–26). According to an animal study, the anti-anxiety effect of UGS might be mediated by serotonin (upregulation of 5HT1A and downregulation of 5HT2A) and glutamate release (glutamate transport by increasing express glutamate transporter mRNA) (27). Despite these scientific findings, herbal medicine may not have the same effect on everyone. Treatment that focuses on symptoms rather than diseases, such as traditional methods, might be more effective (28). In Japan, 15% of RCTs using herbal medicine included a pattern of symptom manifestation diagnosis (29). Therefore, clinical trials in combination with the traditional diagnosis are thought to be a better way to demonstrate traditional East Asian medicine's characteristics. A real-world trial was conducted in this manner, with positive results (30). Therefore, for the above reason, it is considered that the treatment group was more effective on the PDQ-39 than the control group in the post-hoc test of the subgroup with anxiety.

Anxiety is a common non-motor symptom in patients with PD. Concerns about PD, experiences in an “off” state, and neurotransmitter reduction are all known to cause anxiety (31). According to Hannah et al., anxiety is more important than depression in predicting quality of life of the patients with PD (32). In this study, PD patients with anxiety based on item 21 of PDQ-39 were included in the post-hoc analysis. Item 21, anxious, was known to have a strong relationship with the State-Trait Anxiety Inventory (STAI), the most widely used anxiety self-assessment tool (33). The STAI had also been used in several studies to assess anxiety in patients with Parkinson's disease, and it was reliable and valid (34, 35). As a result, we divided the patients into anxiety subgroups based on their responses to item 21.

In the control group with anxiety, there was no significant improvement in PDQ-39 after acupuncture + medications related to Parkinson's disease. Acupuncture's efficacy in alleviating non-motor symptoms in PD is less well known than its effect on alleviating motor symptoms. It mainly showed significant effects on depression or insomnia (6), but in PDQ-39, previous research has shown a variety of results following acupuncture treatment, making it difficult to make a definitive conclusion (36). And the negative effect may have had a role in this trial because the control group was not given placebo medicines.

This study aims to find out whether there was effectiveness and safety in the administration of UGS compared with the control group. However, there was no additional change in clinical symptoms of Parkinson's disease in the treatment group compared to the control group. Only the quality of life of participants with anxiety was significantly affected. Similar results were found in previous studies in which UGS was administered to patients with Parkinson's disease. Although UGS reduced the Neuropsychiatric Inventory (NPI) score, it did not affect the UPDRS III (motor examination) or the H-Y scale (12, 13). Furthermore, Uncaria in UGS exhibited a similar effect as Aripiprazole, an antipsychotic drug that can act as a partial dopamine agonist and cause drug-induced parkinsonism (37). When taken as above, UGS may not be able to aid in the improvement of motor function. However, UGS has been reported to increase dopamine levels with similar effects to catechol-O-methyltransferase (COMT) inhibitors, as well as protect dopamine neurons from neurotoxicity and improve drug-induced parkinsonian symptoms (10, 11, 38, 39). Moreover, UGS was also known to ameliorate dyskinetic movement caused by levodopa (40). Taking these heterogeneous findings into account, more research into the efficacy of UGS is thought to be necessary.

There are some limitations to the present study. First, in this study, the participants in the control group could not be blinded. For this reason, there may be a placebo effect in the treatment group. Second, a 6-week treatment period may not be long enough to obtain the result. Clinical trials examining the effectiveness of herbal medicines in PD had a period of almost 12 weeks or more (9). As a result, the 6-week period may have been insufficient to see the intact effect of UGS. However, even in a short period, the administration of UGS showed significant effectiveness in the anxiety group. Finally, there were mixed cases where "on" and "off" were not the same at the time of measurement. In this trial, "on" and "off" states were analyzed together. However, the "off"-state participant was few, and it is estimated that their impact will not be significant.

Despite the limitations mentioned above, this research had some advantages. This study was a pilot clinical trial to verify the efficacy of herbal medicine UGS based on recent experimental results. The study found that the clinical effectiveness of UGS on QoL examined with PDQ-39 was estimated to be significantly larger in patients with PD and anxiety. The findings of this study can be used as a base for large-scale clinical trials on the efficacy of UGS in the treatment of PD in future.

**Data availability statement**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

CJ, K-HC, and SK conceived the objectives of the study. CJ acquired the data. CJ, B-KK, H-JP, and SK analyzed the data and performed the statistical analysis, which was discussed with W-SJ and T-HK. CJ, K-HC, and SK wrote the first draft of the manuscript. CJ, W-SJ, H-GL, S-YC, S-KM, C-NK, H-JP, and SK co-drafted the final version. K-HC and SK supervised the study. All authors critically revised the manuscript and have approved the final manuscript.

Funding

This work is supported by the grant from the Traditional Korean Medicine R&D Program and funded by the Ministry of Health and Welfare through the Korea Health Industry Development Institute (KHIDI, B16C0051) and the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (No. 2022M3A9B6017813).

Acknowledgments

This paper is based on CJ doctoral dissertation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Poewe W, Seppe K, Taintor CM, Halliday GM, Breundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. (2017) 3:1–21. doi: 10.1038/nrdp.2017.13
2. Dorsey E, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. (2018) 8:53–8. doi: 10.2233/jpd.181474
3. Kalia LV, Lang AE. Parkinson’s disease. Lancet. (2015) 386:896–912. doi: 10.1016/S0140-6736(14)61393-3
4. Bega D, Zadikoff C. Complementary & alternative management of Parkinson’s disease: an evidence-based review of eastern influenced practices. J Movement Disorders. (2014) 7:57. doi: 10.1402/jmd.14009
5. Lee S-H, Lim S. Clinical effectiveness of acupuncture on Parkinson disease: a PRISMA-compliant systematic review and meta-analysis. Medicine. (2017) 96.e5836. doi: 10.1097/MD.0000000000005836
6. Huang J, Qin X, Cai X, Huang Y. Effectiveness of acupuncture in the treatment of Parkinson’s disease: an overview of systematic reviews. Front Neurol. (2020) 11:917. doi: 10.3389/fneur.2020.00917
7. Ko JH, Lee H, Kim S-N, Park H-J. Does acupuncture protect dopamine neurons in Parkinson’s disease rodent model?: a systematic review and meta-analysis. Front Aging Neurosci. (2019) 11:102. doi: 10.3389/fnagi.2019.00102
8. Shan C-S, Zhang H-F, Xu Q-Q, Shi Y-H, Wang Y, Li Y, et al. Herbal medicine formulas for Parkinson’s disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled clinical trials. Front Aging Neurosci. (2018) 10:349. doi: 10.3389/fnagi.2018.00349
9. Zhang G, Xiong N, Zhang Z, Liu L, Huang J, Yang J, et al. Effectiveness of traditional Chinese medicine as an adjunct therapy for Parkinson’s disease: a systematic review and meta-analysis. PLoS ONE. (2015) 10:e0118498. doi: 10.1371/journal.pone.0118498
10. Doo A-R, Kim S-N, Park J-Y, Cho KH, Hong J, Eun-Kyung K, et al. Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. J Ethnopharmacol. (2010) 131:433–42. doi: 10.1016/j.jep.2010.07.008
11. Ishida Y, Ebihara K, Tabuchi M, Imamura S, Sekiguchi K, Mizoguchi K, et al. Yokukansan, a traditional Japanese medicine, enhances the L-DOPA-induced rotational response in 6-hydroxydopamine-lesioned rats: possible inhibition of COMT. Biol Pharmaceut Bull. (2016) 39:104–13. doi: 10.1248/bpb.h15-00691
12. Hatano T, Hattori N, Kawanabe T, Terayama Y, Suzuki N, Iwasaki Y, et al. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson’s disease. J Neural Transm. (2014) 121:275–81. doi: 10.1007/s00702-013-1105-y
13. Kawanabe T, Yoritaka A, Shimura H, Oinumi H, Tanaka S, Hattori N. Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Prog Neuro-Psychopharmacol Biol Psychiatry. (2010) 34:284–7. doi: 10.1016/j.pnpbp.2009.11.019
14. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. J Altern Complement Med. (2010) 16:ST-1-ST-14. doi: 10.1089/acm.2010.1610
15. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Movement Disorders. (2007) 22:41–7. doi: 10.1002/mds.21198
16. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’ disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Aging. (1997) 26:353–7. doi: 10.1093/ageing/26.5.353
17. Kim S-H, Ahn J, Ock M, Shin S, Park J, Luo N, et al. The EQ-5D-5L valuation study in Korea. Qual Life Res. (2016) 25:1845–52. doi: 10.1007/s11136-015-1205-2
Psychogeriatrics. with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine and therapeutic method of diseases. World J Gastroenterol. WJG. (2015) 21:273–80. doi: 10.3389/fagi.2015.676827. PLoS ONE. (2014) 9:e104422. doi: 10.1371/journal.pone.0104422

29. Motoo Y, Arai I, Tsutani K. Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review. PLoS ONE. (2014) 9:e104422. doi: 10.1371/journal.pone.0104422

30. Liang B, Zou F-H, Lu L, Liao H-L. Chinese herbal medicine Dingdi Famai decoction for ventricular premature contraction: a real-world trial. BioMed Res Int. (2020). doi: 10.1155/2020/5358467

31. Chen JJ, Marsh L. Anxiety in Parkinson's disease: identification and management. Ther Adv Neurol Disord. (2014) 7:52–9. doi: 10.1177/1756285613495723

32. Hanka KK, Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson's disease. Parkinson's Disease. (2012) 2012:640707. doi: 10.1155/2012/640707

33. Jones JD, Hass C, Mangal P, Lafo J, Ocun MS, Bowers D. The cognition and emotional well-being indices of the Parkinson's disease questionnaire: what do they really measure? Parkinsonism Relat Disord. (2014) 20:1236–41. doi: 10.1016/j.parkreldis.2014.09.014

34. Matheson SF, Byrne GI, Dissanayaka NN, Pachana NA, Mellick GD, O'Sullivan JD, et al. Validity and reliability of the geriatric anxiety inventory in Parkinson's disease. Australas J Ageing. (2012) 31:13–6. doi: 10.1111/j.1741-6612.2010.00487.x

35. Mondelo F, Jahnshahi M, Graná A, Biasutti E, Cacciatori E, Di Benedetto P. Evaluation of anxiety in Parkinson's disease with some commonly used rating scales. Neurol Sci. (2007) 28:270–5. doi: 10.1007/s10072-007-0834-9

36. Wen X, Li K, Wen H, Wang Q, Wu Z, Yao X, et al. Acupuncture-related therapies for Parkinson's disease: a meta-analysis and qualitative review. Front Aging Neurosci. (2013) 5:268. doi: 10.3389/fnagi.2013.00268

37. Ueda T, Ugasawa S, Ishida Y, Shimada S. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. Eur J Pharmacol. (2011) 671:79–86. doi: 10.1016/j.ejphar.2011.09.007

38. Eo H, Huh E, Sim Y, Oh MS. Ugkansan protects dopaminergic neurons from 6-hydroxydopamine neurotoxicity via activation of the nuclear factor (erythroid-derived 2)-like 2 factor signalling pathway. Neurochem Int. (2019) 122:208–15. doi: 10.1016/j.neuint.2018.11.021

39. Shim Y-H, Park J-Y, Choi W-W, Min J-K, Park S-U, Jung W-S, et al. Herbal medicine treatment for drug-induced parkinsonism. J Alternative Complement Med. (2015) 21:273–80. doi: 10.1089/acm.2014.0124

40. Huh E, Choi JG, Sim Y, Oh MS. An integrative approach to treat parkinson's disease: Ugkansan complements L-Dopa by ameliorating dopaminergic neuronal damage and L-dopa-induced dyskinesia in mice. Front Aging Neurosci. (2019) 10:431. doi: 10.3389/fnagi.2018.00431

18. Pan W, Kwak S, Liu Y, Sun Y, Fang Z, Qin B, et al. Traditional Chinese medicine improves activities of daily living in Parkinson's disease. Parkinson's Dis. (2011) 2011:789506. doi: 10.4061/2011/789506

19. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol. (2010) 67:64–70. doi: 10.1001/archneurol.2009.295

20. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. (2016) 25:1057–73. doi: 10.1177/0962280215588241